These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38444090)

  • 21. Independent Prognostic Utility of
    Choi YJ; Koh Y; Lee HJ; Hwang IC; Park JB; Yoon YE; Kim HL; Kim HK; Kim YJ; Cho GY; Sohn DW; Paeng JC; Lee SP
    J Nucl Med; 2022 Jul; 63(7):1064-1069. PubMed ID: 34916248
    [No Abstract]   [Full Text] [Related]  

  • 22. Utility of B-Type Natriuretic Peptide for Detecting Cardiac Involvement in Immunoglobulin Amyloidosis.
    Kimishima Y; Yoshihisa A; Kiko T; Yokokawa T; Miyata-Tatsumi M; Misaka T; Oikawa M; Kobayashi A; Takeishi Y
    Int Heart J; 2019 Sep; 60(5):1106-1112. PubMed ID: 31484874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased Prognostic Value of Query Amyloid Late Enhancement Score in Light-Chain Cardiac Amyloidosis.
    Wan K; Sun J; Han Y; Liu H; Yang D; Li W; Wang J; Cheng W; Zhang Q; Zeng Z; Chen Y
    Circ J; 2018 Feb; 82(3):739-746. PubMed ID: 29093431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.
    Dispenzieri A; Gertz MA; Saenger A; Kumar SK; Lacy MQ; Buadi FK; Dingli D; Leung N; Zeldenrust S; Hayman SR; Kapoor P; Grogan M; Hwa L; Russell SJ; Go RS; Rajkumar SV; Kyle RA; Jaffe A
    Am J Hematol; 2015 Jun; 90(6):524-8. PubMed ID: 25753178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis.
    Vergaro G; Castiglione V; Aimo A; Prontera C; Masotti S; Musetti V; Nicol M; Cohen Solal A; Logeart D; Georgiopoulos G; Chubuchny V; Giannoni A; Clerico A; Buda G; Patel KN; Razvi Y; Patel R; Wechalekar A; Lachmann H; Hawkins PN; Passino C; Gillmore J; Emdin M; Fontana M
    Eur J Heart Fail; 2023 Mar; 25(3):335-346. PubMed ID: 36597836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin.
    Kumar SK; Gertz MA; Dispenzieri A
    J Clin Oncol; 2019 Jan; 37(2):171-173. PubMed ID: 30433848
    [No Abstract]   [Full Text] [Related]  

  • 27. Left ventricular myocardial work improves in response to treatment and is associated with survival among patients with light chain cardiac amyloidosis.
    Briasoulis A; Bampatsias D; Petropoulos I; Rempakos A; Patras R; Theodorakakou F; Makris N; Dimopoulos MA; Stamatelopoulos K; Kastritis E
    Eur Heart J Cardiovasc Imaging; 2024 Apr; 25(5):698-707. PubMed ID: 38142437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amino-terminal pro-B-type natriuretic peptide as predictor of mortality in patients with symptomatic peripheral arterial disease: 5-year follow-up data from the Linz Peripheral Arterial Disease Study.
    Mueller T; Dieplinger B; Poelz W; Endler G; Wagner OF; Haltmayer M
    Clin Chem; 2009 Jan; 55(1):68-77. PubMed ID: 18988753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
    Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
    Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of survival stratification in patients with wild-type cardiac amyloidosis.
    Siepen FAD; Bauer R; Voss A; Hein S; Aurich M; Riffel J; Mereles D; Röcken C; Buss SJ; Katus HA; Kristen AV
    Clin Res Cardiol; 2018 Feb; 107(2):158-169. PubMed ID: 28956153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.
    Aljama MA; Sidiqi MH; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame RM; Kourelis T; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
    Blood Adv; 2019 Apr; 3(8):1226-1229. PubMed ID: 30975646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new staging system using right atrial strain in patients with immunoglobulin light-chain cardiac amyloidosis.
    Usuku H; Yamamoto E; Sueta D; Shinriki R; Oike F; Tabata N; Ishii M; Hanatani S; Hoshiyama T; Kanazawa H; Arima Y; Takashio S; Kawano Y; Oda S; Kawano H; Ueda M; Tsujita K
    ESC Heart Fail; 2024 Jun; 11(3):1612-1624. PubMed ID: 38400613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor.
    Kristen AV; Rinn J; Hegenbart U; Lindenmaier D; Merkle C; Röcken C; Hardt S; Giannitsis E; Katus HA
    Clin Res Cardiol; 2015 Mar; 104(3):250-7. PubMed ID: 25331161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
    Dispenzieri A; Gertz MA; Kyle RA; Lacy MQ; Burritt MF; Therneau TM; McConnell JP; Litzow MR; Gastineau DA; Tefferi A; Inwards DJ; Micallef IN; Ansell SM; Porrata LF; Elliott MA; Hogan WJ; Rajkumar SV; Fonseca R; Greipp PR; Witzig TE; Lust JA; Zeldenrust SR; Snow DS; Hayman SR; McGregor CG; Jaffe AS
    Blood; 2004 Sep; 104(6):1881-7. PubMed ID: 15044258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.
    Palladini G; Barassi A; Klersy C; Pacciolla R; Milani P; Sarais G; Perlini S; Albertini R; Russo P; Foli A; Bragotti LZ; Obici L; Moratti R; Melzi d'Eril GV; Merlini G
    Blood; 2010 Nov; 116(18):3426-30. PubMed ID: 20644111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.
    Rezk T; Lachmann HJ; Fontana M; Naharro AM; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Hawkins PN; Gillmore JD
    Br J Haematol; 2019 Aug; 186(3):460-470. PubMed ID: 31124579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-sensitivity troponin T improves the prognostic value of N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: results from the LURIC Study.
    Ivandic BT; Spanuth E; Kleber M; Grammer TB; März W
    Clin Chem Lab Med; 2011 Jun; 49(6):1053-8. PubMed ID: 21574877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide predict mortality in stable coronary artery disease: results from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.
    Giannitsis E; Spanuth E; Horsch A; Kleber ME; Koch W; Grammer TB; Koenig W; März W
    Clin Chem Lab Med; 2013 Oct; 51(10):2019-28. PubMed ID: 24072576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biohumoral markers as predictor of right ventricular dysfunction in AL Amyloidosis.
    Cappelli F; Baldasseroni S; Bergesio F; Padeletti L; Attanà P; Pignone AM; Grifoni E; Ciuti G; Fabbri A; Tarantini F; Marchionni N; Gensini GF; Perfetto F
    Amyloid; 2014 Jun; 21(2):97-102. PubMed ID: 24517408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study.
    Ingebrigtsen A; Saeed S; Larsen TH; Reikvam H
    Scand J Clin Lab Invest; 2024 May; 84(3):193-201. PubMed ID: 38709651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.